Skip to main content

Table 1 Clinical and demographic features of the 10 patients with early diffuse SSc

From: Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features

Sex/age (years)

Year of SSc onset/disease duration at skin-BM biopsy (years)

MRSS/score at skin biopsy

Autoantibodies

Lung involvment HRCT/PFT

Heart involvement/scleroderma renal crisis

Raynaud’s phenomenon/digital ulcers

F/46

2010/2

12/2

ANA/Scl-70

Normal/Normal

Normal/No

Yes/No

F/21

2009/3

13/1

ANA/Scl-70

Normal/Normal

Normal/No

Yes/Yes

F/31

2011/1

13/2

ANA/Scl7-0

Normal/Normal

Normal/No

Yes/Yes

F/36

2010/2

11/2

ANA/Scl-70

Normal/Normal

PAH/No

Yes/Yes

M/20

2010/2

11/1

ANA/Scl-70

Normal/Normal

Normal/No

Yes/No

F/41

2010/2

15/2

ANA/Scl-70

Normal/Normal

Normal/No

No/No

F/30

2010/2

10/1

ANA/Scl-70

Normal/Normal

Normal/No

Yes/No

F/21

2010/2

09/1

ANA/Scl-70

Normal/Normal

Normal/No

Yes/No

F/31

2009/3

14/1

ANA/Scl-70

Normal/Normal

Normal/No

Yes/No

F/42

2009/3

16/2

ANA/Scl-70

Fibrosis/Normal

Normal/No

Yes/No

  1. M, male; F, female; MRSS, modified Rodnan skin thickness score (maximum possible score 51); HRCT, high-resolution computed tomography; PFT, pulmonary function test; ANA, antinuclear antibodies; ACA, anti-centromere antibodies; scl-70, anti-topoisomerase antibodies; PAH, pulmonary arterial hypertension.